Vernalis plc company was founded in 1986 and is based in Winnersh, the United Kingdom. Vernalis plc, a development stage pharmaceutical company, engages in de novo structure and fragment-based drug discovery, and pre-clinical and clinical development primarily in Europe and North America. It primarily involves in the research, development, and commercialization of pharmaceutical products for a range of medical disorders. The company’s products include Frovatriptan, a 5-HT1B/1D receptor agonist, which is approved as an acute oral treatment for migraine headache and its associated symptoms; and Apokyn, an acute intermittent therapy for the treatment of re-emergence of Parkinson’s disease symptoms associated with advanced Parkinson’s disease. Its product pipeline comprises V3381/Indantadol, a Phase IIb study novel small molecule with a dual mechanism for the treatment of neuropathic pain; V85546, a Phase I study selective MMP 12 inhibitor for inflammation; V1512/Levodopa methyl ester/carbidopa, a Phase II trial product for Parkinson’s disease treatment; V2006, an adenosine A2A receptor antagonist in Phase IIa study for the treatment of Parkinson’s disease; NVP-AUY922, a novel Hsp90 inhibitor, which is in Phase I program for the treatment of a range of cancers, including solid tumors and hematological cancers; V158866 Fatty Acid Amide Hydrolase, a pre-clinical stage product for pain management; V10153, a Phase IIa recombinant human thrombolytic protein for the treatment of acute ischemic stroke; and V24343, a Phase I study cannabinoid type 1 receptor antagonist for the treatment of obesity, diabetes, and related disorders.

Dako makes disease diagnosis a little more clear-cut. A leader in the area of pathology testing, Dako makes instrumentation systems, reagents, and software used by pathology laboratories to analyze human tissues for the presence of cancer. Its Automated Link line of pathology instruments include staining and visualization systems, chemical and antibody reagents, and Dako Link workflow management software. The company also makes reagents used in flow cytometry testing (which analyzes the cells in blood) and in clinical immunochemistry (which measures proteins in body fluids). The company was acquired by private equity fund EQT in 2007 and subsequently divested its flow cytometry instrumentation business.

DURECT Corporation was founded in 1998 and is based in Cupertino, California. DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. The company's products include POSIDUR, a release formulation of bupivacaine under Phase IIb clinical trial, which is used for the treatment of post-surgical pain; and ELADUR, a transdermal bupivacaine patch under Phase IIb clinical trial that provides continuous delivery of bupivacaine for up to three days from a single application, as well as is used for the treatment of pain associated with post-herpetic neuralgia. DURECT Corporation also offers Remoxy, an oral oxycodone gelatin capsule under development with pain therapeutics; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch under development, which provides continuous delivery of sufentanil for a period of up to seven days from a single application. In addition, the company offers CHRONOGESIC (sufentanil), a pain therapy system; and ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. Further, it designs, develops, and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients for use as raw materials in their products.

VIVUS, Inc. company was founded in 1991 and is headquartered in Mountain View, California. VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in Phase III clinical trials for obesity and in Phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the two of the Phase III studies are in process and one Phase III study has been completed; Qnexa for treating diabetes, for which a one-year Phase II study has been completed; Avanafil, is being developed for the treatment of erectile dysfunction; for which Phase III studies are in process, and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed.

Xencor, Inc. company tailors proteins, not pants. Xencor is developing therapeutics for cancer, inflammatory ailments, and autoimmune diseases. The company engineers antibodies using its Protein Design Automation (PDA) technology, which allows for the specific targeting of diseased cells. Its drug candidates aim to treat cancerous conditions such as Hodgkin's lymphoma, T-cell lymphomas, and B-cell malignancies, as well as other autoimmune diseases. Research partners include Centocor, Genentech, Eli Lilly, and Human Geonome Sciences.

GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.

Founded in 1992, Alpha Innotech Corporation develops, manufactures and markets digital imaging and detection systems for the Life Science research and Drug Discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide. On October 28, 2009 Alpha Innotech became part of Cell Biosciences.

Santa Cruz, California might be known for its sun-baked bodies; Santa Cruz Biotechnology is known for its antibodies. The company makes antibodies used by researchers to identify and treat a variety of conditions. Its products include growth factor antibodies, steroid receptor antibodies, and tumor suppressor antibodies. The company also offers more than 10,000 target-specific small interfering RNA (siRNA), which are used to silence genes. Its siRNAs are designed to silence tumors suppressor proteins, cell cycle proteins, and lymphocyte signaling proteins, among others. Santa Cruz Biotechnology has offices in California, Japan, and Germany and sells its products through distributors worldwide.

Brothers Charles and Theophil Gebauer founded the company in 1898. Gebauer's Salivart will make your mouth water. Seriously, that's what it's designed to do for people who suffer from xerostomia, better known as dry mouth. That's not all Gebauer makes, however. The company offers medications for topical use, including Ethyl Chloride for the treatment of pain; Instant Ice, for the relief of muscle spasms, strains, bruising, and other injuries; and Spray and Stretch, for myofacial pain and minor sports injuries. Gebauer also provides contract manufacturing as well as project planning, packaging and labeling, and distribution services for other drug makers.

Genzyme Diagnostics was founded in 1981. A division of Genzyme, it develops, manufactures, and distributes "in vitro" diagnostic products, including point-of-care tests. The division also produces the raw materials (such as enzymes and antibodies used in tests for diabetes, cholesterol, and pancreatitis) and chemical reagents used by other diagnostic test manufacturers to make their own diagnostic tests. The company's point-of-care products (tests administered at a patient's bedside) include tests for strep A, mononucleosis, and bacterial vaginitis; it also offers several different pregnancy tests.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.